ZINC16991592 is a selective MRGPRX2 antagonist with Ki of 189 nM.

ZYF0033 (ZYF 0033) is potent, selective, small-molecule inhibitor of HPK1 with IC50 of <10 nM based on the phosphorylation inhibition of MBP protein.

ψTnI (Peptide DWRKNIDA) is a selective, high-affinity, eight amino acid peptide inhibitor of cardiac troponin I (cTnI), directly binds to δPKC with high affinity (Kd=5 nM) and inhibits cTnI/δPKC interaction.

7030B-C5 is an effective small-molecule PCSK9 inhibitor with IC50 of 1.61 uM (PCSK9 transcription) in HepG2 cells, with no apparent effect on cell growth and survival.

NYX-1492 is a small molecule PCSK9 inhibitor, blocks PCSK9 binding with the LDLR, attenuates inflammation in vascular cells and tissue-engineered blood vessels (TEBVs).

NYX-PCSK9i is an orally bioavailable small-molecule inhibitor of PCSK9, inhibits PCSK9-LDLR interaction with IC50 of 323 nM in in vitro biochemical binding assays.

BPN-15477 (BPN15477) is a potent splicing modulator compound that restores correct splicing of ELP1 exon 20, increases full-length ELP1 mRNA by increasing exon 20 inclusion with EC50 of 1.9 uM in luciferase splicing assays.

CD33 splicing modulator 1 is a small-molecule CD33 pre-mRNA splicing modulator with EC50 of 7.8 uM, enhances the exclusion of CD33 exon 2, reduces full-length V-domain containing CD33 protein.

HTT splicing modulator 27 is a potent, orally bioavailable, and brain-penetrant small-molecule HTT pre-mRNA splicing modulator with mHTT protein EC50 of 66 nM.

Rebecsinib (17S-FD-895) is a selective small-molecule inhibitor of splicing-mediated ADAR1 activation, prevents leukemia stem cell generation.

Thailanstatin C (TST-C) is a potent antiproliferative natural product, a pre-mRNA splicing inhibitor and antiproliferative agent..

SRI-42127 is a small molecule, BBB-permeable inhibitor of the RNA regulator HuR, inhibits HuR dimerization with IC50 of 1.2 uM in cell-based assays, prevents HuR oligomerization.

STK018404 is a small molecule inhibitor of RNA-binding protein human antigen R (HuR), decreases the binding of HuR to its target RNA motif.

AA132 (AA-132) is a small molecule activator of UPR signaling, covalently modifies a subset of ER protein disulfide isomerases (PDIs), activates global UPR signaling through a mechanism analogous to that of AA147.

AG-946 (AG946) is a potent, allosteric activator of wild-type and mutant RBC-specific form of pyruvate kinase (PKR) with AC50 of 5 nM for human wild-type PK, 4.3 nM and 6.9 nM for mutated K410E and R510Q PK proteins, resepctively.

HA344 (HA 344) is a dual covalent inhibitor of pyruvate kinase M2 (PKM2) and inosine monophosphate dehydrogenase (IMPDH), efficiently inhibits cutaneous metastatic melanoma (CMM).

TAS0612 (TAS-0612) is an orally bioavailable multikinase inhibitor of AKT, p70S6K, and p90RSK, inhibits Y-box-binding protein (YBX1) phosphorylation.

TCMDC-136364 (AKT Kinase Inhibitor) is an Akt kinase inhibitor, selectively inhibits Akt in proliferating cells expressing Trop-2, also potently inhibits P. falciparum multidrug resistant strain Dd2.

BI-9774 (BI 9774) is a potent pan-AMPK activator with EC50 of 64 nM in an ADP-Glo kinase assay with human AMPK (α1β1γ1) and EC50 of 8 nM in a cellular GLUT4 translocation assay.

KI-301670 is a novel potent, specific NUAK1 inhibitor, disturbs NUAK1 signaling by targeting its ATP binding site, effectively inhibits the PI3K/AKT pathway in pancreatic cancer cells.

MSG011 is a potent, pan AMPK isoform activator with EC50 of 140.4 nM, 248.9 nM, 553.4 nM, and 472.9 nM for α1β1γ1, α1β2γ1, α2β1γ1, and α2β2γ1, respectively.

PXL770 is a novel orally bioavailable, small-molecule direct AMPK activator with EC50 of 16.2, 42.1 and 64 nM for α1β1γ1, α1β1γ2 and α1β1γ3, directly increases AMPK activity by both allosteric activation and protection from dephosphorylation.